Clinical trials: Patients with Multiple Sclerosis
Sclerosis, Multiple, MS (Multiple Sclerosis)
EXOPULSE Mollii Suit, Spasticity, Muscular Oxygenation & Multiple Sclerosis (ENNOX 2)
The goal of this clinical trial is to demonstrate the improvement of muscular oxygenation in patients with Multiple Sclerosis and spasticity using Exopulse Molli suit stimulation.
- Conditions
- Sclerosis, Multiple, MS (Multiple Sclerosis), Spastic, Spasticity, Muscle
- Trial name
- NCT05912595
- Testing
- EXOPULSE Mollii Suit Stimulation
- Where
- United Arab Emirates
- Volunteers
- 36 people
- Sponsor
- Sheikh Shakhbout Medical City
Multiple Sclerosis
TELEMS: Feasibility of Remote Patient Visits in MS
This trials randomizes patients with multiple sclerosis (MS, pwMS) to a remote visit (via phone or videochat) or a regular outpatient visit. Outcomes include satisfaction on the patients' and doctor's side.
- Trial name
- TELEMSRCT (NCT04838990)
- Testing
- EDSS, Discussion of symptoms, Patient reported outcome (MSIS)
- Where
- Austria
- Volunteers
- 45 people
- Sponsor
- Medical University of Vienna
Multiple Sclerosis, Relapsing-remitting
Pharmacokinetics of Vitamin D in Multiple Sclerosis and in Health
This is a pilot study of oral vitamin D supplementation to determine if patients with Multiple Sclerosis (MS) and healthy individuals attain a similar increase in serum 25-hydroxyvitamin D levels.
- Trial name
- NCT01667796
- Testing
- Vitamin D3
- Where
- 2 sites in United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Multiple Sclerosis, Iyenagar Yoga, Yoga, EDSS
The Effect of Iyengar Yoga Practice on Patients with Multiple Sclerosis
The aim of this work is to find out what effect the practice of Iyengar yoga has on patients with multiple sclerosis on the EDSS 5 and more, specifically in the field of mobility, self-sufficiency and anxiety.
- Trial name
- NCT05247372
- Testing
- The effect of Iyengar yoga practice on patients with multiple sclerosis
- Where
- Czechia
- Volunteers
- 5 people
- Sponsor
- University Hospital, Motol
Facial Angiofibromas
Topical Everolimus in Patients With Tuberous Sclerosis Complex
Tuberous sclerosis complex (TSC) is a rare genetic multisystem disorder characterized by the development of hamartomas in several organs (e.g. brain, heart, kidney, liver, lung), and skin in more than 90% of cases.
- Trial name
- EVEROST (NCT02860494)
- Testing
- Everolimus
- Where
- France
- Sponsor
- Hospices Civils de Lyon
Multiple Sclerosis
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple Sclerosis
The main purpose of this study is to evaluate the safety and tolerability of the ocrelizumab subcutaneous (SC) test formulation in participants with multiple sclerosis (MS).
- Trial name
- OCARINA 3 (NCT07667322)
- Testing
- Ocrelizumab Co-formulated With rHuPH20
- Where
- 12 sites in United States, Brazil and 2 more
- Volunteers
- 75 people
- Sponsor
- Hoffmann-La Roche
MS Patient With Relpasing Remitting Attacks
Nasal Administration of Dexamethasone for Multiple Sclerosis (MS) Treatment
The study aims to assess the safety and efficacy of nasale administration of Dexamethasone in relapsing MS patients
- Trial name
- NCT00674141
- Testing
- Dexamethasone soduim phosphate
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Hadassah Medical Organization
Multiple Sclerosis
Wireless, Implantable Tibial Nerve Stimulator System (eCoin™) for the Treatment of Refractory Lower Urinary Tract Symptoms in Patients With MS
Prevalence of lower urinary tract symptoms (LUTS) in patients with MS increases with disease duration. Current management of urinary clinical symptoms in MS is mainly conservative.
- Trial name
- NCT03753698
- Testing
- eCoin
- Where
- Switzerland
- Sponsor
- Chiara Zecca
Multiple Sclerosis
Standardized Ambulatory Neurorehabilitation Program for Patients With Multiple Sclerosis
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS) and the most common cause of non-traumatic disability in young adults in western countries.
- Trial name
- "MS-Fit" (NCT02440516)
- Testing
- Early treatment group, Late treatment group
- Where
- 2 sites in Switzerland
- Volunteers
- 65 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Relapsing Remitting Multiple Sclerosis
Disease Control in RRMS Transferring Treatment From Natalizumab to Fingolimod
This is an observational study to develop new hypothesis regarding the dynamic and safety of switching from natalizumab to fingolimod: Comparison of disease activity (clinical and MRI) during the year after change of therapy in…
- Trial name
- NCT02277964
- Where
- Switzerland
- Volunteers
- 25 people
- Sponsor
- University Hospital, Basel, Switzerland
Multiple Sclerosis, Neurogenic Bladder
Neurogenic Lower Urinary Tract Symptoms in Patients With Multiple Sclerosis
There is no consensus in the literature upon the neurourological diagnostic algorithm of the patients with multiple sclerosis (MS). The primary aim of the study is phenotyping the patients with MS.
- Trial name
- NCT05587101
- Testing
- Urodynamic Study (Filling cystometry and pressure-flow study), Questionnaires, Uroflowmetry
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Koç University
Tuberous Sclerosis, Subependymal Giant Cell Astrocytoma
Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex
The purpose of the study is to evaluate the safety and potential side effects of everolimus (an experimental drug) on a person with Tuberous Sclerosis Complex who also has been diagnosed with a brain tumor (astrocytoma) The…
- Trial name
- NCT00411619
- Testing
- Everolimus
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Multiple Sclerosis, Bladder Dysfunction
Alfuzosin for Voiding Dysfunction in Multiple Sclerosis (MS)
Multiple Sclerosis is often associated with severe functional deficits resulting in a range of progressive impairments. Approximately 80% of patients have bladder symptoms at the time of diagnosis and up to 97% will have bladder…
- Trial name
- NCT00688948
- Testing
- Alfuzosin
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Nova Scotia Health Authority
Multiple Sclerosis
Evaluation of Angioplasty in the Treatment of Chronic Cerebrospinal Venous Insufficiency (CCSVI) in Multiple Sclerosis
The study is being done to determine if venous angioplasty is an effective treatment for chronic cerebrospinal venous insufficiency (CCSVI).
- Trial name
- NCT01201707
- Testing
- Angioplasty, Observation
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Community Care Physicians, P.C.
Multiple Sclerosis
Study to Compare the Clinical and Radiological Efficacy of 625 mg Versus 1250 mg of Oral Methylprednisolone in Patients With Multiple Sclerosis in Relapse
The investigators plan to carry out a multicenter randomized clinical trial and MRI study of high-dose oMP (1250mg/day for 3 days) versus lower-high dose oMP (625mg/day for 3 days) and demonstrated that lower-high dose of oMP is…
- Trial name
- NCT01986998
- Testing
- Methylprednisolone 1250 mg/24h x3 days, Oral Methylprednisolone 625 mg/24h x3 days
- Where
- 8 sites in Spain
- Volunteers
- 49 people
- Sponsor
- Germans Trias i Pujol Hospital
Progressive Multiple Sclerosis
A Trial of Bile Acid Supplementation in Patients With Multiple Sclerosis
This study aims to identify the safety and tolerability of bile acid supplementation in patients with progressive Multiple Sclerosis (MS).
- Trial name
- NCT03423121
- Testing
- Tauroursodeoxycholic Acid
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Johns Hopkins University
Multiple Sclerosis, Relapsing-Remitting
Establish Tolerance In MS With Peptide-Coupled, Peripheral Blood Mononuclear Cells
Open-label, single center, phase I clinical trial to assess the safety, tolerability and preliminary efficacy and in vivo mechanisms of action of i.v.
- Trial name
- ETIMS (NCT01414634)
- Testing
- ETIMS
- Volunteers
- 9 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Tumor, Tumor, Solid
Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes
- Conditions
- Tumor, Tumor, Solid, Metastasis, Metastatic Cancer
- Trial name
- NCT05103358
- Testing
- nab-sirolimus
- Where
- 166 sites in United States, Puerto Rico and 1 more
- Volunteers
- 128 people
- Sponsor
- Aadi Bioscience, Inc.
Multiple Sclerosis
Gene Expression in MS Patients Before and During Treatment With Interferon-beta
Clinical and experimental evidences suggest that there is a variability in therapeutic response to immunomodulating therapies in Multiple Sclerosis patients.
- Trial name
- NCT00202384
- Where
- Italy
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- S. Andrea Hospital
Multiple Sclerosis, Insulin Resistance
Insulin Resistance in Egyptian Patients With Multiple Sclerosis
The goal of this three-phase interventional study is to determine the prevalence of Insulin resistance in non-diabetic patients with multiple sclerosis in Egypt The main questions it aims to answer are: 1.
- Trial name
- IR-MS (NCT06017726)
- Testing
- treatment of insulin resistance with appropriate modality according to each patient
- Volunteers
- 100 people
- Sponsor
- Assiut University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.